"I literally woke up, days on end for about 12 weeks with no pain."
That's not something migraine sufferer Lailani Ash has been able to say before.
She is one of 2,000 patients being treated with a new drug called Eptinezumab. Alder BioPharmacuticals created the drug which is in its final phase of development and trials.
About one in eight Americans suffer from migraines.
"You could start your day off feeling perfectly normal and make plans and start to go do something and being completely body slammed with pain," Ash said.
Since she's been on the drug?
"The first several days that I woke up with no pain, I cried," Ash said. "Because I could get up and I could do something. I could be reliable. I could go to dinner with my kids and I could play with my grandkids."
It's not a pill.
"The IV infusion is a simple office visit, takes about 30 minutes and you would only need to do that about four times per year," said Randy Schatzman, president of Alder BioPharmacuticals.
"This class of medications seems very promising," said Dr. Arif Khan, medical director at Northwest Clinical Research. "I think that it should be fast-tracked by the FDA and hopefully we'll have it in the market in the next two to three years."